斯迈旭生物成立于2022年10月，创始人为清华大学饶燏教授，公司最早在全球开展了“单分子双靶”靶向蛋白降解（PROTAC）药物的开发，并率先在国内开展了抗体偶联降解剂（DAC）平台的建立和相关药物的研发。公司管线主要聚焦于自免及肿瘤领域，定位于BIC及FIC，致力于解决难成药靶点及目前未被满足的迫切临床需求的挑战。斯迈旭于2024年12月获颁《北京市专精特新中小企业》，并于2026年1月与清华大学联合获批蛋白降解与分子胶药物北京重点实验室。
SmashBio was founded in October 2022 by Professor Rao Yu from Tsinghua University. The company pioneered the development of "single-molecule dual-target" targeted protein degradation (PROTAC) drugs globally and was the first in China to establish an antibody-conjugated degrader (DAC) platform and conduct related drug R&D. Its pipeline primarily focuses on autoimmune diseases and oncology, aiming for Best-in-Class (BIC) and First-in-Class (FIC) status, dedicated to overcoming challenges associated with undruggable targets and addressing urgent unmet clinical needs.
In December 2024, SmashBio was recognized as a "Beijing Specialized, Refined, Unique, and Innovative Small and Medium Enterprise". Furthermore, in January 2026, it jointly established the "Beijing Key Laboratory for Protein Degradation and Molecular Glue Drugs" with Tsinghua University.